AS/Spondyloarthritis
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
COSMOS: Guselkumab in TNF-IR PsA. # OP0230m Coates LC, et al.
C-…
3 years 6 months ago
Video: The PsA SpA Paradox of Choice
Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at the virtual #EULAR2021 meeting.
https://t.co/Yg12SHR1MF https://t.co/UiCYDU5XGc
3 years 6 months ago
Video: Nr-axSpA vs axSpA — does it matter? Dr. Meral El Ramahi (@MeralElRamahiMD ) #EULAR2021
https://t.co/ocyR4ka8zO https://t.co/DxHjM0stKo
3 years 6 months ago
#EULAR2021 - Day 3 Report
https://t.co/X7zxsKW8eL https://t.co/OKu5Mgodlo
Here are a few notable presentations from Day 3.
BEAT- LUPUS Trial: OP0129 – I would consider this a pilot trial as it only included 52 patients with active SLE, but the gist was that active SLE…
The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress,…
3 years 6 months ago
Find all your AS/Spondyloarthritis coverage from #EULAR2021 in one spot.
https://t.co/owm8LQzHXr https://t.co/5YmDFOvolF
3 years 6 months ago
OP0140 at #EULAR2021:
➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASDAS & multiple bDMARD use (indicating difficult to tx dz)
➡️1 in 10 received at least 3 bDMARDs
*⃣Multiple switchers were more often F, had higher b/l dz activity, & psoriasis
@Rheumnow https://t.co/syq0szVWKe
3 years 6 months ago
⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema) in the spine + SIJ vs PBO in pts w/ active AS
⭐️OP0141 = post-hoc analysis that showed stat signif ⬇️ of CANDEN MRI scores (new bone format) w/ filgot at wk12
#EULAR2021 @Rheumnow https://t.co/RIpYIMcx1Q